Prospective Study of an Explainable AI Tool to Support Biliopancreatic Limb Selection in One-Anastomosis Gastric Bypass (JI-AI-OAGB)
A Study Protocol for Multivariable Regression and Explainable Artificial Intelligence to Support Biliopancreatic Limb Selection in One-Anastomosis Gastric Bypass Using J-I Fat Coverage, Total Small-Bowel Length, and AII
調査の概要
状態
詳細な説明
One-anastomosis gastric bypass is a metabolic-bariatric procedure in which a long gastric pouch is connected to the small bowel by a single gastrojejunostomy. The length of the biliopancreatic limb (BPL) changes the length of bowel exposed to biliopancreatic secretions before mixing with ingested nutrients and may therefore influence weight loss, metabolic response, nutritional risk, and bile/acid reflux. Existing clinical practice includes different BPL lengths, and the available evidence does not establish one universally optimal length for every patient.
This study is designed as a prospective, multicentre, observational cohort for development and external validation of an explainable clinical decision-support model. The study will enrol adults undergoing primary laparoscopic or robot-assisted OAGB as part of routine clinical care. The BPL length will not be assigned by the AI system during model development. The actual clinically selected BPL length will be recorded as an observed exposure together with operative configuration, centre, surgeon, and relevant patient characteristics.
The primary prespecified factor is P_JI, calculated as 100 × FI/JI. JI is the full measured distance from the internal left-hypochondrial trocar point J to the ligament of Treitz at point I. FI is the portion of the J-I instrument segment covered or occupied by the displaced visceral/omental fat layer. P_JI ranges from 0% to 100% and is a laparoscopic geometric coverage metric, not a direct volumetric measurement of total visceral fat.
The second factor is TSBL, measured in centimetres from the ligament of Treitz to the ileocecal junction. TSBL will be used to estimate residual absorptive bowel for each candidate BPL length. A 4-10 m interval may be used as an operational study range, but it is not a universal biological normal range; measurements outside this range will trigger quality review rather than automatic truncation.
The third factor is AII, calculated as (CD/AC) + (CG/EG) + (JI/FI). AII is a secondary geometric and technical feature. When FI equals zero, JI/FI is structurally undefined and must be handled by a prespecified missingness and sensitivity-analysis strategy rather than by substituting an arbitrary value.
The statistical baseline will be multivariable regression appropriate to each endpoint, with centre and surgeon effects handled explicitly. Nested models will compare the incremental contribution of P_JI, TSBL, and AII. Explainable AI will be used as a calibrated prediction and visualization layer, not as an autonomous decision maker. Candidate BPL actions of 0.5, 1, 2, and 3 m will be represented as research actions for analysis. Longer candidates will be subject to residual-bowel, nutritional, anatomical, uncertainty, governance, and follow-up safety constraints.
The proposed hierarchy P_JI greater than TSBL greater than AII is a falsifiable hypothesis. It may be supported, rejected, or revised after out-of-sample validation. The study will report effectiveness and harm endpoints separately and will not use an unvalidated composite outcome as the sole definition of the best BPL length. The final surgeon decision, any model override, and the reason for abstention will be documented.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Oral Ospanov, Professor
- 電話番号：87015287734
- メール：bariatric.kz@gmail.com
研究連絡先のバックアップ
- 名前：Oral Ospanov
- 電話番号：87015287734
- メール：bariatric.kz@gmail.com
研究場所
-
-
Aqmola
-
Astana、Aqmola、カザフスタン、010000
- Oral Ospanov
-
コンタクト：
- Oral Ospanov, Professor
- 電話番号：87015287734
- メール：bariatric.kz@gmail.com
-
コンタクト：
- Oral Ospanov
- 電話番号：87015287734
- メール：bariatric.kz@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Adults aged 18 years or older at the time of consent.
- Patients who meet the institution's independent clinical criteria for primary one-anastomosis gastric bypass.
- Planned laparoscopic or robot-assisted OAGB at a participating centre.
- Ability to undergo standardized intraoperative measurement of the J-I segment, P_JI components, and total small-bowel length when clinically and ethically appropriate.
- Ability to provide informed consent according to local requirements.
- Willingness and reasonable ability to complete the prespecified postoperative follow-up.
Exclusion Criteria:
- Revisional, conversion, or non-primary gastric bypass surgery.
- Operative anatomy that prevents reliable identification or measurement of the ligament of Treitz, the J-I segment, or the ileocecal junction.
- Unaddressed altered gastrointestinal anatomy that is outside the development protocol.
- Severe pre-existing malnutrition or another condition for which experimental variation in BPL length would be considered clinically inappropriate by the treating team.
- Inability to provide informed consent when consent is required.
- Inability to complete the minimum follow-up required by the approved protocol, unless the participant is retained for an approved missing-data or safety analysis.
- Any intraoperative or postoperative circumstance in which the treating surgeon determines that protocol measurement would create unacceptable risk.
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
One-anastomosis gastric bypass with observed biliopancreatic limb length
Participants are followed from OAGB through prespecified outcomes
|
Participants undergo primary laparoscopic or robot-assisted one-anastomosis gastric bypass as part of routine clinical care. The observed biliopancreatic limb length, operative configuration, surgical platform, centre, and surgeon are recorded. During model development, the study does not assign a BPL length and the AI system does not replace the surgeon's clinical judgment. Candidate lengths of 0.5, 1, 2, and 3 m are research-action labels used to evaluate predictions and safety constraints, not automatically assigned treatment arms. Additional exposure variables:
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percent total weight loss at 12 months after OAGB
時間枠：12 months after OAGB
|
Percent total weight loss will be calculated as 100 × (baseline body weight - body weight at 12 months) / baseline body weight.
Baseline weight is measured before OAGB using the site-approved calibrated scale.
The measure is continuous and will be analysed separately from nutritional harm, reflux, major complications, and technical outcomes.
|
12 months after OAGB
|
|
Incremental out-of-sample predictive contribution of P_JI for 12-month percent total weight loss
時間枠：From model development through external validation; primary clinical endpoint assessed at 12 months after OAGB
|
The incremental contribution of P_JI will be evaluated by comparing a prespecified baseline model without the three decision factors with a nested model adding P_JI.
The analysis will report out-of-sample change in Brier score, partial R² or an endpoint-appropriate explained-variation measure, calibration, discrimination, bootstrap confidence intervals, and decision-curve net benefit.
P_JI will be considered the leading factor only if its contribution is reproducibly larger than the incremental contributions of TSBL and AII under the prespecified analysis.
|
From model development through external validation; primary clinical endpoint assessed at 12 months after OAGB
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percent total weight loss at 24 months after OAGB
時間枠：24 months after OAGB
|
Percent total weight loss will be calculated using baseline weight and weight at 24 months.
The measure will be analysed by observed BPL length and in outcome models containing P_JI, TSBL, AII, clinical covariates, centre, surgeon, operative configuration, and candidate-length interactions when supported by the design.
|
24 months after OAGB
|
|
Incremental predictive contribution of total small-bowel length
時間枠：From model development through external validation; clinical outcomes assessed at 12 and 24 months after OAGB
|
The incremental contribution of measured TSBL will be evaluated by comparing the model containing P_JI with a nested model adding TSBL.
TSBL will be analysed continuously in centimetres or after prespecified standardization.
Residual absorptive bowel will be calculated for each observed BPL length.
Performance will be reported with out-of-sample Brier score, calibration, discrimination, partial R² or an endpoint-appropriate explained-variation measure, and confidence intervals.
|
From model development through external validation; clinical outcomes assessed at 12 and 24 months after OAGB
|
|
Incremental predictive contribution of the abdominal integral index
時間枠：From model development through external validation; clinical outcomes assessed at 12 and 24 months after OAGB
|
The incremental contribution of AII will be evaluated by comparing the model containing P_JI and TSBL with a nested model adding AII.
AII will be calculated as (CD/AC) + (CG/EG) + (JI/FI).
Cases in which FI equals zero will be handled as structural missingness for the JI/FI component and analysed using the prespecified missingness and sensitivity-analysis strategy.
|
From model development through external validation; clinical outcomes assessed at 12 and 24 months after OAGB
|
|
Nutritional and malabsorptive safety outcomes
時間枠：Baseline, 3, 6, 12, and 24 months after OAGB, with additional clinically indicated assessments
|
Nutritional and malabsorptive outcomes will be reported separately and will include protein-energy malnutrition, hypoalbuminemia, anaemia, iron or ferritin deficiency, folate deficiency, calcium or vitamin D abnormalities, vitamin B12 deficiency, fat-soluble vitamin deficiency, diarrhoea, steatorrhoea, and need for intensive or parenteral replacement therapy.
Definitions, laboratory thresholds, and clinically significant-event criteria will be prespecified in the statistical analysis plan before database lock.
|
Baseline, 3, 6, 12, and 24 months after OAGB, with additional clinically indicated assessments
|
|
Bile and acid reflux outcomes
時間枠：Baseline and 3, 6, 12, and 24 months after OAGB, with event-based assessment throughout follow-up
|
Bile and acid reflux outcomes will include patient-reported reflux symptoms, need for escalation of medical therapy, endoscopic findings when clinically indicated, marginal ulcer, and revision for clinically significant reflux.
The operative configuration and reflux-prevention technique will be recorded because reflux cannot be attributed to BPL length alone.
|
Baseline and 3, 6, 12, and 24 months after OAGB, with event-based assessment throughout follow-up
|
|
Major clinical complications and reoperation
時間枠：From OAGB through 24 months after surgery
|
Major complications will include anastomotic leak, reoperation, readmission, venous thromboembolism, hospitalization, mortality, and other protocol-defined serious adverse events.
Events will be adjudicated according to the approved study definitions and reported separately from weight-loss effectiveness.
|
From OAGB through 24 months after surgery
|
|
Technical feasibility and measurement reproducibility
時間枠：Intraoperative period and immediately after the operation
|
Technical outcomes will include operative time, conversion from laparoscopic or robot-assisted surgery, inability to complete the planned reconstruction, revision of the planned BPL length, intraoperative bowel injury, blood loss, instrument exchanges, and surgeon-rated workload.
Measurement reproducibility will include repeated AC, CD, CG, EG, KI, JI, FI, and TSBL measurements, intraclass correlation coefficient, coefficient of variation, and frequency of measurement-related abstention.
|
Intraoperative period and immediately after the operation
|
|
Safety-gated candidate BPL eligibility and algorithm abstention
時間枠：At intraoperative decision-support evaluation and through 24-month follow-up
|
For candidate BPL lengths of 0.5, 1, 2, and 3 m, the study will record whether the candidate passes prespecified residual-bowel, nutrition, anatomy, follow-up, model-applicability, and uncertainty checks.
The study will report the frequency and reasons for algorithm abstention, surgeon override, and suppression of longer research-only candidates.
This outcome evaluates workflow safety and does not represent proof of clinical benefit.
|
At intraoperative decision-support evaluation and through 24-month follow-up
|
協力者と研究者
捜査官
- 主任研究者：Oral Ospanov, Professor、Astana Medical University
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。